{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:07:27Z","timestamp":1760400447355,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["15Ik0109082h0002","15ek0109082h0001","16Ik0109082h0003","16ek0109082h0002"],"award-info":[{"award-number":["15Ik0109082h0002","15ek0109082h0001","16Ik0109082h0003","16ek0109082h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["16k10155"],"award-info":[{"award-number":["16k10155"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jdermsci.2019.05.002","type":"journal-article","created":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T19:49:15Z","timestamp":1557776955000},"page":"350-353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficiency of sirolimus delivery to the skin is dependent on administration route and formulation"],"prefix":"10.1016","volume":"94","author":[{"given":"Kazuko","family":"Kitayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Wataya-Kaneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jdermsci.2019.05.002_bib0005","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: a new generation of mTOR inhibitors","volume":"10","author":"Benjamin","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.jdermsci.2019.05.002_bib0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jdermsci.2015.04.005","article-title":"Mammalian target of rapamycin and tuberous sclerosis complex","volume":"79","author":"Wataya-Kaneda","year":"2015","journal-title":"J. Dermatol. Sci."},{"issue":"9861","key":"10.1016\/j.jdermsci.2019.05.002_bib0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet (London, England)"},{"issue":"9869","key":"10.1016\/j.jdermsci.2019.05.002_bib0020","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet (London, England)"},{"issue":"17","key":"10.1016\/j.jdermsci.2019.05.002_bib0025","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jdermsci.2019.05.002_bib0030","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jaad.2015.07.018","article-title":"Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus","volume":"73","author":"Nathan","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"issue":"7","key":"10.1016\/j.jdermsci.2019.05.002_bib0035","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jamadermatol.2018.1408","article-title":"Sirolimus gel treatment vs placebo for facial angiofibromas in patients with tuberous sclerosis complex: a randomized clinical trial","volume":"154","author":"Wataya-Kaneda","year":"2018","journal-title":"JAMA Dermatol."},{"issue":"1","key":"10.1016\/j.jdermsci.2019.05.002_bib0040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jdv.12665","article-title":"Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex","volume":"29","author":"Balestri","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol.: JEADV"},{"key":"10.1016\/j.jdermsci.2019.05.002_bib0045","series-title":"Chemical Penetration Enhancers: Classification and Mode of Action","first-page":"11","author":"Dragicevic","year":"2015"}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181119301173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181119301173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:49:57Z","timestamp":1760330997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181119301173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0923181119301173"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2019.05.002","relation":{},"ISSN":["0923-1811"],"issn-type":[{"type":"print","value":"0923-1811"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficiency of sirolimus delivery to the skin is dependent on administration route and formulation","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2019.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V. on behalf of Japanese Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}